Bengaluru to host the prestigious 3rd Annual India Leadership Conclave 2012
Asia’s Biggest & India’s Much awaited 3rd Annual India Leadership Conclave & Indian Affairs Business Leadership awards 2011 to focus on Brand India
Maharashtra, Mumbai, India, Wednesday, Feb 8, 2012 : Indian Brands are as crazy as is its innovators are, as Indians constantly innovate. A close scrutiny of Indian Brands post the free economy era will reveal that large number of players in diverse sectors have made their mark in their respective fields notwithstanding the hurdles & government regulation from time to time. Today Brand India is globally accepted as the world Market is looking at india as the most preferred destination for collaboration, partnerships & investments. India is a land of billion opportunities and not a billion problems . In the last 20 years, the country has added a trillion dollars of output. The last decade has seen India emerge stronger on the world map, especially during the global financial meltdown when the country weathered the crisis much to the admiration of the world. India today stands poised at the threshold of change. India, today, has emerged as one of the decisive nations shaping the contours of the world economy. Consistently charting a growth path over the last few years, Brand India is an idea whose time has truly arrived. Today, the triumph of Brand India is visible in almost all fields. With some aggressive cross-border acquisitions, India has been rewriting the global business equations; India has established its leadership in IT and knowledge-based industries globally and has the fastest growing population of workers and consumers. With huge investments in infrastructure development on the anvil, India today is a preferred investment destination. It has one of the world’s most rapidly growing markets, and today, Indian products and services are recognised for their quality all over the world.
Against the backdrop of the above backgrounder, where Brand India matters most, Indian Affairs(www.indianaffairs.in) , India’s first pink Magazine is hosting the high profile & india’s most eagerly awaited leadership event, the 3rd Annual India Leadership Conclave & Indian Affairs Business Leadership Awards 2012 in association with the Ministry of Corporate Affairs, Government of India on Friday, 6th April at Hotel Lalit, Bengaluru, India. Keeping its tradition of bringing the finest think-tanks of the society from the different diverse sectors like the much acclaimed two Annual Events ( 1st Annual India Leadership Conclave( www.ilcbusinessleaders.com ) in Delhi & 2nd Annual India Leadership Conclave( www.indialeadershipconclave.in ) in Mumbai), the stage is set for the third one under the theme “ BRAND INDIA – THE EMERGING SUPER POWER, LIMITLESS LEADERSHIP, LIMITLESS POSSIBILITIES.Announcing the Event, satya Brahma, Chairman & editor-In-chief of Indian Affairs magazine said “ 3rd Annual India Leadership Conclave 2012 will bring into forefront the critical issues & will seek to debate how the Brand India has moved over the years by the elite speakers”. More than 200 Industry stalwarts from who’s & who’s of India’s core diverse sectors such as Agriculture, Automobiles, Auto Components, Aviation, Education and Training, Engineering, Financial Services, Food Industry, Insurance, IT & ITeS, Manufacturing, Media and Entertainment, Retail, Science and Technology, Banking, Biotechnology, Cement, Consumer Markets, Healthcare, Infrastructure, Oil and Gas, Pharmaceuticals, Real Estate & Infrastructure, Steel, Textiles, Telecommunications, Tourism and Hospitality will attend the Annual Leadership Conclave. The Conclavewill have the powerful voices from the stalwarts of the Indian inc on topics of tremendous significance on Indian Inc’s complex issues.
3rd Annual India Leadership Conclave Award Categories – 2012.
1. India’s Most Valuable Private Bank :
2. India’s Most Valuable Public Bank
3. India’s Most Promising & Valuable Infrastructure Company
4. India’s Most Valuable 4 Wheeler Company
5. BusinessLeader of the Year
6. BusinessWoman of the Year
7. India’s Best Managed Hospitality Group
8. India’s Most Valuable IT & Web Solution Provider Company
9. India’s Most Promising Real Estate & Infrastructure Company
10. India’s Most Valuable & Best Managed Medical Tourism Company
11. Innovative CEO of The Year
12. Excellence in Social Service
13. India’s Dynamic Entrepreneur of The Year
14. India’s Most Valuable IT Software Company
15. India’s Most Valuable Telecom Company
16. India’s Most Valuable Consumer FMCG Company
17. India’s Most Valuable IT Global Career Company for Masses
18. India’s Most Valuable Pharmaceutical Company
19. India’s Most Promising Retail Pharmacy Company
20. India’s Most Valuable Energy Company
21. India’s Most Valuable Legal Firm
22. Outstanding Contribution to Indian Cinema
23. India’s Most Valuable Broadcast Electronic Media.
24. India’s Most Promising Agricultural Biotech Company.
25. Social Enterprise of the Year
26. Outstanding Contribution to Indian Cinema : Actress of the Substance.
27. First Generation Entrepreneur of the year Award
28. Best Retailer of the Year
29. Global Indian Achievers Award
30. India’s Most Valuable Business School of the Year :
Muddasir R
Head – Media Cell
Indian Affairs
Network 7 Media Group, 510/22 , R.R.Residency,
14th Main, 1st Cross, 1st Stage, Near SBM, MSR Road,
Mathikere, Bengaluru-560054
Tel : +91 80 42138295
Where india wakes up when oppression & tyranny pose a threat. No mercy, only protest through non-violent means
Tuesday, February 7, 2012
Friday, February 3, 2012
Union Budget 2012-13 should promote investment oppourtunities on Agriculture and Biotech sector - Sushil Karwa, MD, Krishidhan Seeds.
Union Budget 2012-13 should promote investment oppourtunities on Agriculture and Biotech sector - Sushil Karwa, MD, Krishidhan Seeds.
Essential Quality Seeds need top priority for seed Rsearch and seed companies should be given a status of infrastructure companies.
Maharastrha, Mumbai, Friday, 3rd Jan2012 : Krishidhan Seeds KSPL which focuses on Agriculture and Biotech sector told Network 7 Media Group’s Indian Affairs Magazine ( www.indianaffairs.in ) & Pharmaleaders Magazine (www.pharmaleaders.co.in )that as it is one of the top three seed companies which is actively involved in research, production, processing, packing, and marketing of high quality seeds of Cotton, Cereals, Pulses, Oil seeds and Vegetables. Speaking to explain its expectations from the Union Budget 2012-13, Mr. Sushil Karwa, MD, Krishidhan Seeds emphasized that “For enhancing the agricultural yield, quality seeds are most essential. In India, farmers are still struggling to get quality seeds because there is no encouragement for seed companies to invest in seed research. To promote seed research, seed companies should be given a status of infrastructure companies and income of seed companies should be treated as agri. income. Finance extended to seed companies should be treated as priority sector lending in the banks. Govt. is extending various subsidies for distribution of oil seeds, pulses seeds, hybrid paddy seeds etc. only to Govt. owned seed corporations. This makes private seed companies uncompetitive. Hence, private seed companies are not investing desirable resources in this segment, because of which, the productivity is stagnant in these crops. Subsidies should be extended to private seed companies also.Price deregulation, particularly in cotton is essential otherwise new technology will not come to India as there is no price differentiation between good & bad”.
It may be recalled that Krishidhan Seeds is one of the fastest growing and amongst the top three seed companies in India with National and International presence. The Group focuses on ushering prosperity of the farming community both at National and International level. The company is actively involved in research, production, processing, packing, and marketing of high quality seeds of Cotton, Cereals, Pulses, Oil seeds and Vegetables. The R&D activities and research stations of Krishidhan are recognized by the Department of Scientific and Industrial Research (DSIR), Govt. of India.
Mr. Sushil Karwa, MD, Krishidhan Seeds expressed hopes that the Union Budget will take into consideration the growing demands of Seeds & Agriculture Companies to promote Farmer’s Research to boost the efficiency of quality seeds. He further stated that the Seeds Companies which are involved in Biotech Research must be given special priorities as agriculture in india is the biggest sector.
Essential Quality Seeds need top priority for seed Rsearch and seed companies should be given a status of infrastructure companies.
Maharastrha, Mumbai, Friday, 3rd Jan2012 : Krishidhan Seeds KSPL which focuses on Agriculture and Biotech sector told Network 7 Media Group’s Indian Affairs Magazine ( www.indianaffairs.in ) & Pharmaleaders Magazine (www.pharmaleaders.co.in )that as it is one of the top three seed companies which is actively involved in research, production, processing, packing, and marketing of high quality seeds of Cotton, Cereals, Pulses, Oil seeds and Vegetables. Speaking to explain its expectations from the Union Budget 2012-13, Mr. Sushil Karwa, MD, Krishidhan Seeds emphasized that “For enhancing the agricultural yield, quality seeds are most essential. In India, farmers are still struggling to get quality seeds because there is no encouragement for seed companies to invest in seed research. To promote seed research, seed companies should be given a status of infrastructure companies and income of seed companies should be treated as agri. income. Finance extended to seed companies should be treated as priority sector lending in the banks. Govt. is extending various subsidies for distribution of oil seeds, pulses seeds, hybrid paddy seeds etc. only to Govt. owned seed corporations. This makes private seed companies uncompetitive. Hence, private seed companies are not investing desirable resources in this segment, because of which, the productivity is stagnant in these crops. Subsidies should be extended to private seed companies also.Price deregulation, particularly in cotton is essential otherwise new technology will not come to India as there is no price differentiation between good & bad”.
It may be recalled that Krishidhan Seeds is one of the fastest growing and amongst the top three seed companies in India with National and International presence. The Group focuses on ushering prosperity of the farming community both at National and International level. The company is actively involved in research, production, processing, packing, and marketing of high quality seeds of Cotton, Cereals, Pulses, Oil seeds and Vegetables. The R&D activities and research stations of Krishidhan are recognized by the Department of Scientific and Industrial Research (DSIR), Govt. of India.
Mr. Sushil Karwa, MD, Krishidhan Seeds expressed hopes that the Union Budget will take into consideration the growing demands of Seeds & Agriculture Companies to promote Farmer’s Research to boost the efficiency of quality seeds. He further stated that the Seeds Companies which are involved in Biotech Research must be given special priorities as agriculture in india is the biggest sector.
Thursday, February 2, 2012
Dr. Kannan Vishwanath Led Aanjaneya Lifecare buys Apex Drugs valued at Rs 250 crore Pharma Acquisition rolls on SMES as to Increase Financial & product portfolio
Pharmaleaders Magazine reported a news story on 31st Jan 2012 that Aanjaneya Lifecare is close to acquire a domestic Pharma Company & On 2nd February 2012, Aanjaneya Lifecare declared the completion of the acquisition of Apex Drugs and Intermediates Ltd (ADIL), an integrated API and pharma intermediates manufacturing company based in Hyderabad. The acquisition was valued at Rs. 250 crore ; with Debt of Rs. 185 crores and equity dilution of Rs. 65 Crores.
Aanjaneya Lifecare Ltd has acquired ADIL’s assets, businesses, clients, licensees, employees and has merged both the companies’ operations, becoming a fully integrated formulation company. The company will also leverage the strong relations of ADIL developed in Asia, Europe, UAE & Latin America for exports. The acquistion also gives Aanjaneya an entry in Hyderabad market. Post acquisition Aanjaneya Lifecare will have approximate sales of Rs.700 crores with EBITDA of Rs.130 crore and total long term debt in books of about Rs.220 crore against networth of Rs. 365 crore. (The company’s debt to equity ratio would be less than 1). In monetary terms, Aanjaneya Lifecare can sell 40% of the APIs into formulations and formulation sales would be three times the API sales.
The acquisition would widen the footprints of the company through its easy access to the product portfolio of ADIL and enable it to cross–sell the products to ADIL’s customer base. The product portfolio of Aanjaneya Lifecare will be widened by ADIL’s API business of Aids, HIV, Diabetes, Ace inhibitors and CNS. The acquisition has saved time that would have taken 3-4 years time to secure clearances.
Aanjaneya Lifecare with its strong presence in API and formulation business, the company in future also plans to expand its product portfolio to lifestyle segment. This will enable the company to have diversified product portfolio which will help it to become a fully integrated formulation company.
Commenting on the acquisition of Apex Drugs and Intermediates, Dr. Kannan Vishwanath, Vice Chairman and Managing Director of Aanjaneya Lifecare Ltd said,” We are very pleased to announce the acquisition of Apex Drugs and Intermediates Ltd (ADIL).It will reduce the company’s dependence on third parties for pricing and supply to a large extent.Going further the company also plans to enter into lifestyle segment. The acquisition will not only strengthen Aanjaneya Lifecare’s presence in the Hyderabad market but would also expand its stronger growth footprint in their market”.
Monday, January 30, 2012
Aanjaneya Lifecare Posts Robust Growth, net up by 75% in Q3, Inches Close To Acquisition
Aanjaneya Lifecare Posts Robust Growth, net up by 75% in Q3, Inches Close To Acquisition
Sets Out To Reach An Ambitious Plan To Reach 500 Crore By 2014
Maharastra , Mumbai, Tuesday 31st Jan 2012 : Mumbai based Mid Sized Indian Pharma major Aanjaneya Lifecare Limited is charting out its expansion plan p0st the robust performance of quarter ended December 31, 2011 with sales zooming to1075 million for the quarter ended December 31, 2011; YoY growth over Q3 FY 2011 of 62% & PAT is Rs.121 million for the quarter ended December 31, 2011; YoY growth of 75% with the overall Results for the 9 months ended December 31, 2011 & the Sales are Rs.3188 million for the 9 months ended December 31, 2011; YoY growth over 9MFY2011 of 44% & PAT is Rs. 357 million for the 9 months ended December 31, 2011; YoY growth of 58%. The Mumbai-based pharma company is engaged in the manufacture of anti-malarial active pharmaceutical ingredients (APIs) and herbal medicines, inhalers, lozenges and animal health products. The company is the world's third-largest manufacturer of quinine salts used in the treatment of malaria. It is also one of the country's largest contract manufacturers of codeinebased cough syrups. The money ( Rs 117 crore) raised by the company through its IPO is being used to build new capacities and for the revamp of its R&D centre. With new capacities to be added in the next 6-9 months, the company aims to expand its operations in the emerging markets of South East Asia, Africa & South & Central America, It also plans to grow its domestic operations in the branded generics segment. The company has a market capitalisation of Rs 612 crore. Aanjaneya Lifecare, a Rs.320 crore plus Mumbai based pharma company, has posted strong financial performance during the third quarter ended December 2011. Its net profit surged by 74.9 per cent to Rs.12.14 crore from Rs.6.94 crore in the corresponding period of last year. Its EBDITA also jumped by 88 per cent to Rs.33.94 crore from Rs.18.05 crore. Its net sale went up by 62.5 per cent to Rs.107.57 crore during the quarter under review from Rs.66.21 crore in the similar period of last year. After the announcement of strong performance, Aanjaneya scrip moved up by Rs.14.95 or over 3 per cent to Rs.503.50 on BSE.
The above background is a clear indication to show that Aanjaneya Lifecare is al set to expand its business both domestic as well as international market. A close scrutiny of Company’s growth record wll reveal that from a modest beginning in the year 2006 till date ( since last 5 years), it has made remarkable growth defying all odds & marching ahead with its growth strategy. Its Visionary Vice-Chairman & Managing Director Dr Kannan Vishwanath who will turn 36 this year is leaving no stones unturned to make a formidable presence in the 68,000 crore Indian pharma market. Aanjaneya Lifecare stunned the biggies in the healthcare sector in the year 2011 by raising Rs 117 crore) raised by the company through its IPO at a time when many analysts viewed as a gambling, however, Dr Kannan proved to the point & lived up to the expectations to its stakeholders. We all know that pharmaceutical business in india is very risky yet lucrative if managed well, Dr Kannan just understood the pulse of the market & launched products that will give high margins. The coming days will be a real testing time as how the Company is poised to take its growth drive & fuel the success mantras.
In an exclusive interview to satya Brahma, Editor-In-Chief of Pharmaleaders & Indian Affairs magazine ( www.pharmaleaders.co.in www.indianaffairs.in , beaming Dr Kannan Vishwanath was quite emphatic when asked about his gameplan & success mantra as he says “ In Healthcare Business, Aanjaneya Lifecare was always focused to what it wanted to do no matter how risky & zigzags the roads are..I am quite optimist that backed by a battery of strong professionals within the company, we are here to mark our mark & provide molecules at an affordable rates. He went out to say that Aanjaneya Lifecare will soon make its foray into some of the biggest markets in the world & reach a magic figure of 500 Crore by the turn of 2014”. He however declined to make any comments on the acquisition front. But sources close to Pharma Leaders reveal that indeed Aanjaneya Lifecare is very close to acquire a domestic pharma company to widen its product basket. The deal could be the game changer for Aanjaneya Lifecare as I will add extra products & market presence”. Although the magnitude of the acquisition is not known despite many attempts to ask the company, but it could well within be 40 to 50 Crore if sources to the Pharmaleaders are to be believed.
For the first nine months of 2011-12, Aanjaneya recorded sales growth of 44 per cent to Rs.318.81 crore as against Rs.221.46 crore and its net profit increased by 58.3 per cent to Rs.35.79 crore from Rs.22.61 crore. EBDITA touched to Rs.88.55 crore from Rs.52.99 crore, registering a growth of 67.1 per cent. The earnings per share worked out to Rs.30.91 on an enlarged equity capital at Rs.12.58 as against Rs.29.70 on an old equity capital of Rs.7.58 crore. The company recently raised about Rs.117 crore from its IPO and the funds are being used to built new capacities alongwith the refurbishing of Research & Development centre. The new facilities being created as part of CAPEX are using eco friendly, recyclable material and will be rated by LEEDS once completed, company sources informed. The Facilities being established will comply with the latest European & US guidelines. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operation in branded generics segment. Commenting on the financial performance of the Company Dr. Kannan Vishwanath, Vice Chairman and Managing Director of Aanjaneya Lifecare Ltd said,”We are very pleased with our financial results as our company is growing and will continue doing the same in future. The company’s business growth startegy has resulted in the over all good performance which can be seen in the performance for the quarter ended December 31, 2011. The company has performed excellent and it assures the sharesholders that the company will continue performing good in future too”.
A Brief Overview of Aanjaneya Lifecare Limited
Aanjaneya Lifecare Limited ( ALL ) is one of India’s emerging research based integrated pharmaceutical company with established manufacturing & marketing capabilities headquartered in Mumbai India. The product portfolio of the company includes highly Innovative Alkaloids, Anti Malarial APIs & Anti Cancer APIs from Natural Sources & Veterinary APIs. In Finished Dosages we cover important therapeutic areas such as Anti Malarial, Anti Cancer, Erectile Dysfunction, Hormone Replacement Therapy, Anti Obesity, Herbal products & Lozenges for various Therapeutic segments. Our strength lies in an excellent track record of regulatory approvals & ability to produce a broad range of pharmaceuticals and dosages, like solid, semi-solid, liquid, Gels, Ointments & Lozenges & strong R&D capability, with particular expertise in technically challenging products.
In short span of 6 years we have emerged as third largest manufacturer of Anti-malarial Bulk Drugs Quinine salts in world with presence in 61 countries. We have 5 world patents filed for non infringing route of synthesis for manufacturing Anti Cancer APIs. In Formulations We have introduced for first time in India & emerging markets Nicco-Nil (Hard Boiled Lozenges) containing Nicotine for Quitting Smoking . We have a Pipeline of 75 products to be introduced in phases. . As part of Corporate Social Responsibility program the company has upgraded the school toilets, the class rooms & roofing of an all Girls high School in Mahad , Maharashtra State India. We have constructed Temporary Sheds & housing arrangement for Stray animals in Monsoon for an NGO IDA (In Defense of Animals Our Initial Public Offering in May 2011 was well received & we have been listed in both the premier stock exchanges in India , Bombay Stock Exchange & National Stock Exchange & trading over 40 % premium to our listing price. Aanjaneya Lifecare Introduced for the First Time in Emerging markets of Kenya Tanzania & Dominican Republic Nicco-Nil An OTC product For Quitting Smoking. Introduced 10 products in Lozenges dosage forms which are sugar free & Novel Drug Delivery Systems & available in OTC for Mouth Ulcers ( Ulsacare ) , Prostrate Cancer ( Curcumacare ) , Insomnia ( Relacs) , Appetite enhancers for children ( Apitcatch ) , Arecta Plus ( Erectile Dysfunction ) , Livchek ( Liver Protection ) ,Ezmove ( Mild Laxative) , Natroumune ( Immunity Booster ) & Flukil ( Swine Flu Protector ) . Have invested in Rain Water Harvesting in both our manufacturing facilities & harvest Rain Water in Monsoon for our requirements, further Installed Solar Panels for energy requirements of our utilities, new blocks have been constructed using Eco Friendly recyclable material & The blocks are in process of being rated by LEEDS as Platinum Star . Aanjaneya Lifecare Received the Green Business of the Year Awards at Emerging India Awards held by CNBC TV-18 & ICICI Bank at Macau inNovember 2010 . Aanjaneya Lifecare recently received two prestigious recognitions at 4th Annual Pharma Leadership Summit & Awards 2011. PharmaLeaders, an international bi-monthly magazine & Indo-American Chamber of Commerce, honoured Aanjaneya Lifecare with two prestigious awards “Emerging Pharma Company of Year 2011” & “India’s Most Technically Advanced Manufacturing Facility of the year 2011” at a glittering ceremony in Mumbai held at Hotel Intercontinental at a gala event on Saturday 10th December 2011. The Company has Grown at CAGR of 175 % in last 4 years having state of the Art Facilities which have WHO GMP approval, ISO 9001:2008, ISO 14000 :- 2008 & ISO 22000:2005 accreditation. Aanjaneya Lifecare debuted in the premier stock exchanges of India, Bombay Stock Exchange & National stock Exchange in May 2011 & are being traded at about 40 % premium of listed prices . As part of Corporate Social Responsibility program the company has upgraded the school toilets, the class rooms & roofing of an all Girls high School in Mahad , Maharashtra State India. We have constructed Temporary Sheds & housing arrangement for Stray animals in Monsoon for an NGO IDA (In Defense of Animals ) in Mankhurd – Mumbai.
Dr Kannan Vishwanath
Vice Chairman & Managing Director
Aanjaneya Lifecare Limited
Dr Kannan Vishwanath founded Aanjaneya Lifecare Limited in 2006. He has completed his Chemical Engineering in Pune & Masters & Doctorate of Philosophy in Business Management from University of Azteca. He has over 12 years Experience in Pharmaceutical Industry with expertise in Licensing, Business Development, API, Generics, Finished Dose, Intermediates, marketing, production, distribution, licensing, outsourcing, contract development, formulation development. Patience and Risk Taking are among the motivational factors applied by Dr Vishwanath and they have helped the company to learn from past mistakes and in making better decisions in future. A believer in fair practices, this visionary leader always offers his hand when needed regardless a friend or foe. Dr Vishwanath believes: “when you have a gream , don’t let anything dim it . Keep hoping, keep trying , for Sky is the Limit.
Coming from a very humble beginning with just 40 employees and small manufacturing facility for anti malarial drugs over 6 years ago , Dr Vishwanath has achieved exceptional results through developing and redefining the business roadmap, ensuring differentiation as a competitive advantage and clearly focusing on the brands consumers want and the products consumers need . Anjaneya Lifecare Limited (ALL ) produces & markets a range of pharmaceutical products across the globe . With two facilities in Maharashtra state employing over 300 people the company delivers essential products for every day life under the brands Rankorex, Prosils, DocTor quore, Esyhil, amongst others. The company has over 200 distributors pan India for its Branded Generic products & exports to over 40 countries with sales in excess of 320 crores. Under Dr Vishwanath’s leadership, the marketind, reachersh & product development departments were expanded . The company has been growing at CAGR of 175 % for last 5 years and is now the third largest manufacturer of Quinine salts in world. ALL has received many awards and accolades which recognize its brands and product excellence , such as the Green Business of the year-2011 at Emerging India Awards by ICICI Bank & CNBC TV 18 & voted among the top 100 company in “ India’s Best Companies to Work With -2011 “
PROFESSIONAL SUMMARY
Innovative and results driven leader focused on achieving exceptional results in highly competitive environments that demand continuous improvement. Experience in driving product, process and customer service improvement while building partnerships with key business decision makers
Consistently increased production, reduced operating costs and improved product quality by utilizing world class manufacturing concepts ( lean manufacturing six sigma, theory of constraints etc ) to optimise & rationalize manufacturing processes and supply chain networks Known for building and motivating cross functional teams that exceed corporate expectations.
PROFESSIONAL EXPERIENCE
Promoter & Managing Director
Aanjaneya Lifecare Limited (1/2006 - Present)
Mumbai India.
India’s largest manufacturer of Quinine salts
• Transitioned company transformation from a family owned business to a merger and acquisition and management buyout of a formulation company & integrating business
• Drove he operational planning and successful execution for doubling product lines manufacturing capacity to exploit market growth opportunities.
• Achieved two site turnarounds within two years , bringing operational metrics to baseline standard , while maintaining and improving permanent priorities of safety quality service appearance and people
• Leadership and aggressive development of the company's Formulations business. Identification of market blockbusters and strategies for organic and inorganic growth of formulation segments.
• Drive the company's initiative to become a formulations driven company with a clear focus of making the Formulations business account for 60% of the company's Revenue.
• Building winning teams and driving aggressive growth not just in terms of Year on Year growth but in terms of market shares in the segments the company chooses to work in.
• Sustain and grow the existing pipeline and develop the pipeline for the future. Ability to separate the winners from the losers and dropping losers early in the game is key.
Director (International Sourcing, Business Development & Planning)
BENZOCHEM LIFESCIENCES PVT LTD (1999-2006)
ISO 90001:2000.ISO 14001:2004 & India leading manufacturer of oncology APIs
• Was responsible for a Team of 50 people with $ 10 million budget including supply chain functions two sites, distribution network all inclusive from product conception, procurement, planning through quality and operations to customer delivery.
• Presented and gained approval from the board of directors and executed capital expenditure of 4 million USD with ROI of 5 years
• Developed an effective blend of best practice, teamwork-based culture combined with execution of organizational goals, strategies and measures, which supported the turnaround of the company from near bankruptcy to a stable . rapidly growing business
• Created a cohesive product supply leadership team and provided one-on-one coaching capitalizing on each person’s strengths to deliver high customer satisfaction and quality levels at the lowest total delivered cost.
• Developed communicated and educated product supply leaders and employees on the key profit drivers and tied performance, rewards and recognition to those results. This resulted in cost savings of over 250,000 USD per year.
• Led a core team of engineering research and development and marketing employees who redesigned and implemented upgraded product line up with achieved improved customer satisfaction , superior product
EDUCATION
MIT PUNE- MAHARASHTRA India.
Bachelor of Engineering
Asia-E-University .
Masters in Business Administration
IIRM – Univerisity of Azteca
Doctor of Philosophy in Business Management
International University of Vienna
Honorary Doctorate
PUBLICAT IONS AND RESEARCH
The Study of Individuals Organizational & Environmental Determinants of Innovation by Kannan Vishwanath
Co-Authored & published patents of Tran’s dermal formulations
A NOVEL HYDRO ALCOHOLIC GEL AND /OR CREAM FORMULATION OF METHANDIEONE AND BOLDENONE FOR SAFE DRUG DELIVERY 212673 - 23/MUM/2005
A NOVEL HYDRO ALCOHOLIC GEL AND/OR CREAM FORMULATION OF TOPICAL STEROID OF TRENBOLONE ACETATE AND 212674 - 22/MUM/2005
A NOVEL TRANSDERMAL GEL AND/OR CREAM FORMULATION
212676 - 19/MUM/2005
A NOVEL HYDRO ALCOHOLIC GEL AND /OR CREAM FORMULATION OF NANDROLONE DERIVATIVES
212692 - 20/MUM/2005
A NOVEL HYDRO-ALCOHOLIC GEL AND/OR CREAM FORMULATION OF ANDROSTEN -17-01-3-ONE DERIVATIVES FOR SAFE DRUG DELIVERY SYSTEM
212752 - 21/MUM/2005
MEMBERSHIPS
Indo American chamber of Commerce
Indo African chamber of Commerce
Indo German Chamber of Commerce
Indian Merchant Chambers
AWARDS & HONORS
The European Quality Award 2008 on Behalf of Aanjaneya Biotech Pvt Ltd
The Bizz Award 2008 on behalf of Aanjaneya Biotech Pvt Ltd
OTHER ACCOMPLISHEMNENTS, RESPONSIBILITIES & PARTICIPATION
Community Service Projects:
In Defence of Animals
Provided temporary shelters for 100 animals during monsoon Season. Donated an ambulance for emergency situations for animals at centre in Mumbai India
Sets Out To Reach An Ambitious Plan To Reach 500 Crore By 2014
Maharastra , Mumbai, Tuesday 31st Jan 2012 : Mumbai based Mid Sized Indian Pharma major Aanjaneya Lifecare Limited is charting out its expansion plan p0st the robust performance of quarter ended December 31, 2011 with sales zooming to1075 million for the quarter ended December 31, 2011; YoY growth over Q3 FY 2011 of 62% & PAT is Rs.121 million for the quarter ended December 31, 2011; YoY growth of 75% with the overall Results for the 9 months ended December 31, 2011 & the Sales are Rs.3188 million for the 9 months ended December 31, 2011; YoY growth over 9MFY2011 of 44% & PAT is Rs. 357 million for the 9 months ended December 31, 2011; YoY growth of 58%. The Mumbai-based pharma company is engaged in the manufacture of anti-malarial active pharmaceutical ingredients (APIs) and herbal medicines, inhalers, lozenges and animal health products. The company is the world's third-largest manufacturer of quinine salts used in the treatment of malaria. It is also one of the country's largest contract manufacturers of codeinebased cough syrups. The money ( Rs 117 crore) raised by the company through its IPO is being used to build new capacities and for the revamp of its R&D centre. With new capacities to be added in the next 6-9 months, the company aims to expand its operations in the emerging markets of South East Asia, Africa & South & Central America, It also plans to grow its domestic operations in the branded generics segment. The company has a market capitalisation of Rs 612 crore. Aanjaneya Lifecare, a Rs.320 crore plus Mumbai based pharma company, has posted strong financial performance during the third quarter ended December 2011. Its net profit surged by 74.9 per cent to Rs.12.14 crore from Rs.6.94 crore in the corresponding period of last year. Its EBDITA also jumped by 88 per cent to Rs.33.94 crore from Rs.18.05 crore. Its net sale went up by 62.5 per cent to Rs.107.57 crore during the quarter under review from Rs.66.21 crore in the similar period of last year. After the announcement of strong performance, Aanjaneya scrip moved up by Rs.14.95 or over 3 per cent to Rs.503.50 on BSE.
The above background is a clear indication to show that Aanjaneya Lifecare is al set to expand its business both domestic as well as international market. A close scrutiny of Company’s growth record wll reveal that from a modest beginning in the year 2006 till date ( since last 5 years), it has made remarkable growth defying all odds & marching ahead with its growth strategy. Its Visionary Vice-Chairman & Managing Director Dr Kannan Vishwanath who will turn 36 this year is leaving no stones unturned to make a formidable presence in the 68,000 crore Indian pharma market. Aanjaneya Lifecare stunned the biggies in the healthcare sector in the year 2011 by raising Rs 117 crore) raised by the company through its IPO at a time when many analysts viewed as a gambling, however, Dr Kannan proved to the point & lived up to the expectations to its stakeholders. We all know that pharmaceutical business in india is very risky yet lucrative if managed well, Dr Kannan just understood the pulse of the market & launched products that will give high margins. The coming days will be a real testing time as how the Company is poised to take its growth drive & fuel the success mantras.
In an exclusive interview to satya Brahma, Editor-In-Chief of Pharmaleaders & Indian Affairs magazine ( www.pharmaleaders.co.in www.indianaffairs.in , beaming Dr Kannan Vishwanath was quite emphatic when asked about his gameplan & success mantra as he says “ In Healthcare Business, Aanjaneya Lifecare was always focused to what it wanted to do no matter how risky & zigzags the roads are..I am quite optimist that backed by a battery of strong professionals within the company, we are here to mark our mark & provide molecules at an affordable rates. He went out to say that Aanjaneya Lifecare will soon make its foray into some of the biggest markets in the world & reach a magic figure of 500 Crore by the turn of 2014”. He however declined to make any comments on the acquisition front. But sources close to Pharma Leaders reveal that indeed Aanjaneya Lifecare is very close to acquire a domestic pharma company to widen its product basket. The deal could be the game changer for Aanjaneya Lifecare as I will add extra products & market presence”. Although the magnitude of the acquisition is not known despite many attempts to ask the company, but it could well within be 40 to 50 Crore if sources to the Pharmaleaders are to be believed.
For the first nine months of 2011-12, Aanjaneya recorded sales growth of 44 per cent to Rs.318.81 crore as against Rs.221.46 crore and its net profit increased by 58.3 per cent to Rs.35.79 crore from Rs.22.61 crore. EBDITA touched to Rs.88.55 crore from Rs.52.99 crore, registering a growth of 67.1 per cent. The earnings per share worked out to Rs.30.91 on an enlarged equity capital at Rs.12.58 as against Rs.29.70 on an old equity capital of Rs.7.58 crore. The company recently raised about Rs.117 crore from its IPO and the funds are being used to built new capacities alongwith the refurbishing of Research & Development centre. The new facilities being created as part of CAPEX are using eco friendly, recyclable material and will be rated by LEEDS once completed, company sources informed. The Facilities being established will comply with the latest European & US guidelines. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operation in branded generics segment. Commenting on the financial performance of the Company Dr. Kannan Vishwanath, Vice Chairman and Managing Director of Aanjaneya Lifecare Ltd said,”We are very pleased with our financial results as our company is growing and will continue doing the same in future. The company’s business growth startegy has resulted in the over all good performance which can be seen in the performance for the quarter ended December 31, 2011. The company has performed excellent and it assures the sharesholders that the company will continue performing good in future too”.
A Brief Overview of Aanjaneya Lifecare Limited
Aanjaneya Lifecare Limited ( ALL ) is one of India’s emerging research based integrated pharmaceutical company with established manufacturing & marketing capabilities headquartered in Mumbai India. The product portfolio of the company includes highly Innovative Alkaloids, Anti Malarial APIs & Anti Cancer APIs from Natural Sources & Veterinary APIs. In Finished Dosages we cover important therapeutic areas such as Anti Malarial, Anti Cancer, Erectile Dysfunction, Hormone Replacement Therapy, Anti Obesity, Herbal products & Lozenges for various Therapeutic segments. Our strength lies in an excellent track record of regulatory approvals & ability to produce a broad range of pharmaceuticals and dosages, like solid, semi-solid, liquid, Gels, Ointments & Lozenges & strong R&D capability, with particular expertise in technically challenging products.
In short span of 6 years we have emerged as third largest manufacturer of Anti-malarial Bulk Drugs Quinine salts in world with presence in 61 countries. We have 5 world patents filed for non infringing route of synthesis for manufacturing Anti Cancer APIs. In Formulations We have introduced for first time in India & emerging markets Nicco-Nil (Hard Boiled Lozenges) containing Nicotine for Quitting Smoking . We have a Pipeline of 75 products to be introduced in phases. . As part of Corporate Social Responsibility program the company has upgraded the school toilets, the class rooms & roofing of an all Girls high School in Mahad , Maharashtra State India. We have constructed Temporary Sheds & housing arrangement for Stray animals in Monsoon for an NGO IDA (In Defense of Animals Our Initial Public Offering in May 2011 was well received & we have been listed in both the premier stock exchanges in India , Bombay Stock Exchange & National Stock Exchange & trading over 40 % premium to our listing price. Aanjaneya Lifecare Introduced for the First Time in Emerging markets of Kenya Tanzania & Dominican Republic Nicco-Nil An OTC product For Quitting Smoking. Introduced 10 products in Lozenges dosage forms which are sugar free & Novel Drug Delivery Systems & available in OTC for Mouth Ulcers ( Ulsacare ) , Prostrate Cancer ( Curcumacare ) , Insomnia ( Relacs) , Appetite enhancers for children ( Apitcatch ) , Arecta Plus ( Erectile Dysfunction ) , Livchek ( Liver Protection ) ,Ezmove ( Mild Laxative) , Natroumune ( Immunity Booster ) & Flukil ( Swine Flu Protector ) . Have invested in Rain Water Harvesting in both our manufacturing facilities & harvest Rain Water in Monsoon for our requirements, further Installed Solar Panels for energy requirements of our utilities, new blocks have been constructed using Eco Friendly recyclable material & The blocks are in process of being rated by LEEDS as Platinum Star . Aanjaneya Lifecare Received the Green Business of the Year Awards at Emerging India Awards held by CNBC TV-18 & ICICI Bank at Macau inNovember 2010 . Aanjaneya Lifecare recently received two prestigious recognitions at 4th Annual Pharma Leadership Summit & Awards 2011. PharmaLeaders, an international bi-monthly magazine & Indo-American Chamber of Commerce, honoured Aanjaneya Lifecare with two prestigious awards “Emerging Pharma Company of Year 2011” & “India’s Most Technically Advanced Manufacturing Facility of the year 2011” at a glittering ceremony in Mumbai held at Hotel Intercontinental at a gala event on Saturday 10th December 2011. The Company has Grown at CAGR of 175 % in last 4 years having state of the Art Facilities which have WHO GMP approval, ISO 9001:2008, ISO 14000 :- 2008 & ISO 22000:2005 accreditation. Aanjaneya Lifecare debuted in the premier stock exchanges of India, Bombay Stock Exchange & National stock Exchange in May 2011 & are being traded at about 40 % premium of listed prices . As part of Corporate Social Responsibility program the company has upgraded the school toilets, the class rooms & roofing of an all Girls high School in Mahad , Maharashtra State India. We have constructed Temporary Sheds & housing arrangement for Stray animals in Monsoon for an NGO IDA (In Defense of Animals ) in Mankhurd – Mumbai.
Dr Kannan Vishwanath
Vice Chairman & Managing Director
Aanjaneya Lifecare Limited
Dr Kannan Vishwanath founded Aanjaneya Lifecare Limited in 2006. He has completed his Chemical Engineering in Pune & Masters & Doctorate of Philosophy in Business Management from University of Azteca. He has over 12 years Experience in Pharmaceutical Industry with expertise in Licensing, Business Development, API, Generics, Finished Dose, Intermediates, marketing, production, distribution, licensing, outsourcing, contract development, formulation development. Patience and Risk Taking are among the motivational factors applied by Dr Vishwanath and they have helped the company to learn from past mistakes and in making better decisions in future. A believer in fair practices, this visionary leader always offers his hand when needed regardless a friend or foe. Dr Vishwanath believes: “when you have a gream , don’t let anything dim it . Keep hoping, keep trying , for Sky is the Limit.
Coming from a very humble beginning with just 40 employees and small manufacturing facility for anti malarial drugs over 6 years ago , Dr Vishwanath has achieved exceptional results through developing and redefining the business roadmap, ensuring differentiation as a competitive advantage and clearly focusing on the brands consumers want and the products consumers need . Anjaneya Lifecare Limited (ALL ) produces & markets a range of pharmaceutical products across the globe . With two facilities in Maharashtra state employing over 300 people the company delivers essential products for every day life under the brands Rankorex, Prosils, DocTor quore, Esyhil, amongst others. The company has over 200 distributors pan India for its Branded Generic products & exports to over 40 countries with sales in excess of 320 crores. Under Dr Vishwanath’s leadership, the marketind, reachersh & product development departments were expanded . The company has been growing at CAGR of 175 % for last 5 years and is now the third largest manufacturer of Quinine salts in world. ALL has received many awards and accolades which recognize its brands and product excellence , such as the Green Business of the year-2011 at Emerging India Awards by ICICI Bank & CNBC TV 18 & voted among the top 100 company in “ India’s Best Companies to Work With -2011 “
PROFESSIONAL SUMMARY
Innovative and results driven leader focused on achieving exceptional results in highly competitive environments that demand continuous improvement. Experience in driving product, process and customer service improvement while building partnerships with key business decision makers
Consistently increased production, reduced operating costs and improved product quality by utilizing world class manufacturing concepts ( lean manufacturing six sigma, theory of constraints etc ) to optimise & rationalize manufacturing processes and supply chain networks Known for building and motivating cross functional teams that exceed corporate expectations.
PROFESSIONAL EXPERIENCE
Promoter & Managing Director
Aanjaneya Lifecare Limited (1/2006 - Present)
Mumbai India.
India’s largest manufacturer of Quinine salts
• Transitioned company transformation from a family owned business to a merger and acquisition and management buyout of a formulation company & integrating business
• Drove he operational planning and successful execution for doubling product lines manufacturing capacity to exploit market growth opportunities.
• Achieved two site turnarounds within two years , bringing operational metrics to baseline standard , while maintaining and improving permanent priorities of safety quality service appearance and people
• Leadership and aggressive development of the company's Formulations business. Identification of market blockbusters and strategies for organic and inorganic growth of formulation segments.
• Drive the company's initiative to become a formulations driven company with a clear focus of making the Formulations business account for 60% of the company's Revenue.
• Building winning teams and driving aggressive growth not just in terms of Year on Year growth but in terms of market shares in the segments the company chooses to work in.
• Sustain and grow the existing pipeline and develop the pipeline for the future. Ability to separate the winners from the losers and dropping losers early in the game is key.
Director (International Sourcing, Business Development & Planning)
BENZOCHEM LIFESCIENCES PVT LTD (1999-2006)
ISO 90001:2000.ISO 14001:2004 & India leading manufacturer of oncology APIs
• Was responsible for a Team of 50 people with $ 10 million budget including supply chain functions two sites, distribution network all inclusive from product conception, procurement, planning through quality and operations to customer delivery.
• Presented and gained approval from the board of directors and executed capital expenditure of 4 million USD with ROI of 5 years
• Developed an effective blend of best practice, teamwork-based culture combined with execution of organizational goals, strategies and measures, which supported the turnaround of the company from near bankruptcy to a stable . rapidly growing business
• Created a cohesive product supply leadership team and provided one-on-one coaching capitalizing on each person’s strengths to deliver high customer satisfaction and quality levels at the lowest total delivered cost.
• Developed communicated and educated product supply leaders and employees on the key profit drivers and tied performance, rewards and recognition to those results. This resulted in cost savings of over 250,000 USD per year.
• Led a core team of engineering research and development and marketing employees who redesigned and implemented upgraded product line up with achieved improved customer satisfaction , superior product
EDUCATION
MIT PUNE- MAHARASHTRA India.
Bachelor of Engineering
Asia-E-University .
Masters in Business Administration
IIRM – Univerisity of Azteca
Doctor of Philosophy in Business Management
International University of Vienna
Honorary Doctorate
PUBLICAT IONS AND RESEARCH
The Study of Individuals Organizational & Environmental Determinants of Innovation by Kannan Vishwanath
Co-Authored & published patents of Tran’s dermal formulations
A NOVEL HYDRO ALCOHOLIC GEL AND /OR CREAM FORMULATION OF METHANDIEONE AND BOLDENONE FOR SAFE DRUG DELIVERY 212673 - 23/MUM/2005
A NOVEL HYDRO ALCOHOLIC GEL AND/OR CREAM FORMULATION OF TOPICAL STEROID OF TRENBOLONE ACETATE AND 212674 - 22/MUM/2005
A NOVEL TRANSDERMAL GEL AND/OR CREAM FORMULATION
212676 - 19/MUM/2005
A NOVEL HYDRO ALCOHOLIC GEL AND /OR CREAM FORMULATION OF NANDROLONE DERIVATIVES
212692 - 20/MUM/2005
A NOVEL HYDRO-ALCOHOLIC GEL AND/OR CREAM FORMULATION OF ANDROSTEN -17-01-3-ONE DERIVATIVES FOR SAFE DRUG DELIVERY SYSTEM
212752 - 21/MUM/2005
MEMBERSHIPS
Indo American chamber of Commerce
Indo African chamber of Commerce
Indo German Chamber of Commerce
Indian Merchant Chambers
AWARDS & HONORS
The European Quality Award 2008 on Behalf of Aanjaneya Biotech Pvt Ltd
The Bizz Award 2008 on behalf of Aanjaneya Biotech Pvt Ltd
OTHER ACCOMPLISHEMNENTS, RESPONSIBILITIES & PARTICIPATION
Community Service Projects:
In Defence of Animals
Provided temporary shelters for 100 animals during monsoon Season. Donated an ambulance for emergency situations for animals at centre in Mumbai India
Thursday, January 5, 2012
Price Control of Medicines are detrimental for India’s Healthcare Growth Story & Drives – Kewal Handa, MD, Pfizer & Wyeth India.
Price Control of Medicines are detrimental for India’s Healthcare Growth Story & Drives – Kewal Handa, MD, Pfizer & Wyeth India.
Health Insurance & Availability should be the focus & not the Govt’s Draft Policy. Canada & Philippines growth is due to non-Price Control.
Maharashtra, Mumbai, Friday 6th January 2011 : Union Health Ministry's plan to bring 348 drugs of the National List of Essential Medicines (NLEM) under price control is facing stiff resistance from the pharma industry. A close scrutiny will reveal that around 75% of the industry will come under price control in case the draft National Pharmaceuticals Pricing Policy (NPPP, 2011) is pursued in its present form. Cautioning that it will cripple the pharma sector, Kewal Handa, said the government estimates that the new policy would bring 60% of the Rs 48,200-crore domestic formulation industry under the pricing control compared to 20% earlier. The ministry says, more than 300 drugs were under the Drug Price Control Order (DPCO) in the early 1980s that was subsequently reduced to 140 in 1987. At present, prices of only 74 bulk drugs and formulations, containing any of these scheduled drugs, are under the price control regime. Once a medicine is brought under DPCO, it cannot be sold at a price higher than that fixed by the government. NLEM has 348 medicines that cover 489 formulations, including 16 fixed-dose combinations. These drugs are considered to be adequate to meet the common contemporary health needs of the general population.
Addressing at 4th Annual Pharmaceutical Leadership Summit & Awards 2011 in Mumbai (www.pharmasummit.in ) organized by Asia’s leading Pharma bi-monthly Pharma Leaders Magazine ( www.pharmaleaders.co.in ) , Kewal Handa, Managing Director of Pfizer & Wyeth, Handa said Price Control has become redundant & is unnecessary & instead it will create more troubles & hit the healthcare Industry. In an exclusive Keynote address Handa said The DPCO 1995 has been there for more than a decade, what is the learning of all these in the past, the number of players that were there in DPCO has been substantially come down & the number of molecules have also drastically come down. The number of new introductions in the old DPC0 ( Drug Price Control Authority) are less than that which are there in outside purview of DPCO. Ironically One Third of the products that are there in 1995 have gone to China. Therefore price control does not work & If you look at the global experiences, you will find the correct assessment. Lets look at Canada when the price control was introduced, in a span of three years the Research & Development ( R & D) came down by 50%. Look at Brazil, you will find there also similar experience . And the prices in Philippines are reduced almost by 50 % & who got benefited of all these exercises, the Branded Generic players, the movers from Generics to Branded Generic Players. Now we have a similar experience in India, which is difficult to understand, as the reason given to reduce the price is quite disturbing . If you look at the history of price rises in India since last five years you will see clearly that the price rise is not more than 2% in DPCO as well as in the non DPCO Categories. And if you look at the competition, it is very intense & fierce , for every molecule we have not less than 50 players competing & if that’s the scenario in india where the prices are lowest in the world, is there the need to reduce the prices? Is there a need to bring everything to a single conversant price?? do you want to accommodate our healthcare industry. Do you want to play with the lives of the people cautions Kewal Handa.
He goes on to say that today we need a different treatment, we need to increase our accessibility, we need to increase our availability & more importantly we need to provide Healthcare Insurance to the needy who cant afford to medical treatment . Almost 60% of Indian population can afford to have mobile phones & there is only 15 % of Indian population who has health insurance & this 60% of people who own mobile phones takes the health coverage & the rest are denied of their basic needs& on the light of the above I don’t think so there will be any need for price control or price reduction. All that you need is critical mass coverage. We need to think & debate how to get this critical mass so that chronic diseases can be covered so that middle class population can avail of affordable medicines. The large chunk of Indian population should get access to basic medicines. He concludes saying “I believe that discussion should be on partnership & Accessibility & india has a very good track record of Price Control which is self regulator. I think the Govt should leave it this method as it is”.
Thursday, December 15, 2011
Ranbaxy Global Consumer Healthcare & Aanjaneya Lifecare Declared Winners In “Neutraceutical Segments” & “Company Of The Year Award” Respectively at 4th Annual Pharmaceutical Leadership Awards 2011
Ranbaxy Global Consumer Healthcare & Aanjaneya Lifecare Declared Winners In “Neutraceutical Segments” & “Company Of The Year Award” Respectively at 4th Annual Pharmaceutical Leadership Awards 2011
Kewal Handa Of Pfizer & Aditi Kare Of Indoco Are Business Leaders While Pfizer, Abbott, GSK, Microlabs, Elder Pharmaceuticals, Fortis, Bharat Biotech, Adriot Are Biomed Among Those Win The Race In Important Categories.
Mumbai : 16th December 2011 : 4th Annual Pharmaceutical Leadership Summit & Awards 2011 ( www.pharmasummit,in ) organized by India’s leading bi-monthly Pharma Magazine ( www.pharmaleaders.co.in ) & IACC culminated in high notes as 23 categories of various Nominations were declared Winners in a sequel to 60 days of votings & Juries final verdict. Among those Companies & Individuals who were declared Winners for their outstanding performance in fiercely competitive India Pharma Market are 1.Business Leader of the Year 2011 : Mr KewalHanda, Managing Director, Pfizer India Ltd. 2.Business Woman of the Year 2011 ( Gen-Next Pharma Leader), MrsAditi Kare Panandikar, Whole Time Director, Indoco Remedies Ltd. 3.Dynamic Entrepreneur of the Year 2011: Dr Krishna Ella, CMD, Bharat Biotech International Ltd. 4.Pharma OTC Company of the Year 2011: Ranbaxy Global Consumer Healthcare. 5.India’s Most Admired Nutrition &Neutraceuticals of the Year 2011, Revital Woman & Abbott Healthcare Pvt Ltd. 6.Company of the Year 2011: Venus Remedies Ltd.7.Pharma CSR Organisation of the Year 2011: Ranbaxy Labs Ltd. 8.Pharma Professional Of the Decade 1.Dr Ajit.V.Dangi, CEO & President, Danseen Consulting. 2. Mr RanjitShahani, Vice-Chairman & MD, Novartis India Ltd,3. Narayan Gad, CEO, Formulations, Panacea Biotech Ltd. 9.Brand of the Year 2011: Revital&Volini. 10.Innovative R & D Company of the Year 2011, Bharat Biotech International Ltd. 11.Emerging Brand of The Year :B-COLEN RANGE of Galpha Labs. 12.India’s Most Admired Foundation in Social Innovation: Right to Vision Programme of Wockhardt Foundation. 13.Pharma Achiever of the year in SME,Dr. Rege's Laboratories.14.India’s Most Admired Company in Blood and Biological Products 2011,Synergy Diagnostics Pvt Ltd. 15.India's Most Admired Pharma Company 2011: Microlabs Ltd. 16.India's Most Watched Company of the Year 2011, Elder Pharmaceuticals Ltd,17. Emerging Company of the Year 2011,AanjaneyaLifecare Ltd. 18.India’s Most Admired Company in Exports 2011:Genom Biotech Pvt Ltd. 19.Research Scientist of the Year 2011: Dr. Rashmi Barbhaiya, MD & CEO, Advinus Therapeutics Pvt Ltd. 20.Multinational Company of The Year 2011. ( Joint Winners)1. Pfizer India Ltd, 2. Glaxo SmithKline Pharmaceuticals Ltd.21.India’s Most Admired Hospital Chain 2011. Fortis Healthcare Ltd. 22.Biotech Research Company of The Year 2011. Adroit Biomed Ltd.23.India’s Most technically & scientifically advanced Pharmaceutical Manufacturing unit of the year 2011. Aanjaneya Lifecare Ltd.
Speaking on the Award Declarations, Mr Satya Brahma, Chairman of Network 7 Media Group said “ Pharmaleaders salute these shining stars who bagged these coveted Awards by a rare display of achievements & performed under a changed healthcare scenario”.
With an aptly theme of Generation Next Indian Pharma Leaders, Billionaire Minds, Drivers for Growth at 4th Annual Pharmaceutical Leadership Summit & Awards 2011, veterans of the India’s Healthcare Industry debated on many topics that grappled Indian Healthcare segments. In an opening address, Mr Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders Magazine ( www.pharmaleaders.co.in ) said “ Indian Healthcare Industry has emerged out as a global super Power & has displayed remarkable display of manufacturing excellence & quality medicines & is way ahead of many developed nations, it is only a matter of time that it will overtake China in coming days, he added. He also lamented at Policy Makers & Authorities for slow decision making process specially in the context of Draft Pricing Policy & FDI in Healthcare Sector & urged the Ministry to hear the voices of the healthcare industry”.
Amonth those who addressed at Asia’s Biggest Leadership Meet are Mr. S. Krishnakumar (KK), Market Leader ( Life Sciences)Future Steps ( A Korn/Ferry Company, Dr Lalit S Kanodia, President Indo-American Chamber of Commerce, (IACC), Western Region, & CMD, Datamatics Ltd. Should drug prices be regulated?Mr. Kewal Kanda, MD, Pfizer India Ltd.` India – An Emerging Pharmaceutical Powerhouse , Dr Ajit V Dangi, Board Chairman, Fulford India Ltd. President & CEO, Danseen Consulting. Dr. Rashmi Barbhaiya , CEO and Managing Director - Advinus Therapeutics Ltd “From Scientist To CEO. The vision: Create a Pharmaceutical company focused on discovering and developing the next generation of high end commercialized medicines.Recent Advancements in Blood & Biological products :Mr Sanjay Bawsay, Managing Director, Synergy Diagnostics Pvt Ltd. Human biotechnology research in India, with emphasis on the BBIL story.Mr. Sai D Prasad, Project Manager - Rotavirus Vaccine Project and Vice President - Business Development. Are FDI & Price Control Policy in Indian Pharma Sector deterrent for growth & Globalize Indian Healthcare Industry. Mr. Shashikant B. Shinde ,Whole Time Director, AanjaneyaLifecare Ltd. Differentiate or Die - Pharmaceutical Industry in India. Mr.DeepakNaik, Managing Director Health 'N' U Therapeutics Pvt. Ltd. MrAnand Desai, National President, IACC & Managing Partner, DSK Legal : Do Pharmaceutical Companies Have Debt Crisis Strategy?. A Legal Perspective. Mr Narayan Gad, CEO, Formulations, Panacea Biotech Ltd. Moving Beyond the Healthcare Debate : The Transformative Trends That Will REALLY Define Our Future. Pharma’s Value Proposition - How The Industry Must Change. Perspectives On Current Industry Challenges .Mr. Sunil Madhok, Director, Business Development, Pfizer India Ltd.
More details of the post event are available on requests at editor.in.chief@pharmaleaders.co.in .
Kewal Handa Of Pfizer & Aditi Kare Of Indoco Are Business Leaders While Pfizer, Abbott, GSK, Microlabs, Elder Pharmaceuticals, Fortis, Bharat Biotech, Adriot Are Biomed Among Those Win The Race In Important Categories.
Mumbai : 16th December 2011 : 4th Annual Pharmaceutical Leadership Summit & Awards 2011 ( www.pharmasummit,in ) organized by India’s leading bi-monthly Pharma Magazine ( www.pharmaleaders.co.in ) & IACC culminated in high notes as 23 categories of various Nominations were declared Winners in a sequel to 60 days of votings & Juries final verdict. Among those Companies & Individuals who were declared Winners for their outstanding performance in fiercely competitive India Pharma Market are 1.Business Leader of the Year 2011 : Mr KewalHanda, Managing Director, Pfizer India Ltd. 2.Business Woman of the Year 2011 ( Gen-Next Pharma Leader), MrsAditi Kare Panandikar, Whole Time Director, Indoco Remedies Ltd. 3.Dynamic Entrepreneur of the Year 2011: Dr Krishna Ella, CMD, Bharat Biotech International Ltd. 4.Pharma OTC Company of the Year 2011: Ranbaxy Global Consumer Healthcare. 5.India’s Most Admired Nutrition &Neutraceuticals of the Year 2011, Revital Woman & Abbott Healthcare Pvt Ltd. 6.Company of the Year 2011: Venus Remedies Ltd.7.Pharma CSR Organisation of the Year 2011: Ranbaxy Labs Ltd. 8.Pharma Professional Of the Decade 1.Dr Ajit.V.Dangi, CEO & President, Danseen Consulting. 2. Mr RanjitShahani, Vice-Chairman & MD, Novartis India Ltd,3. Narayan Gad, CEO, Formulations, Panacea Biotech Ltd. 9.Brand of the Year 2011: Revital&Volini. 10.Innovative R & D Company of the Year 2011, Bharat Biotech International Ltd. 11.Emerging Brand of The Year :B-COLEN RANGE of Galpha Labs. 12.India’s Most Admired Foundation in Social Innovation: Right to Vision Programme of Wockhardt Foundation. 13.Pharma Achiever of the year in SME,Dr. Rege's Laboratories.14.India’s Most Admired Company in Blood and Biological Products 2011,Synergy Diagnostics Pvt Ltd. 15.India's Most Admired Pharma Company 2011: Microlabs Ltd. 16.India's Most Watched Company of the Year 2011, Elder Pharmaceuticals Ltd,17. Emerging Company of the Year 2011,AanjaneyaLifecare Ltd. 18.India’s Most Admired Company in Exports 2011:Genom Biotech Pvt Ltd. 19.Research Scientist of the Year 2011: Dr. Rashmi Barbhaiya, MD & CEO, Advinus Therapeutics Pvt Ltd. 20.Multinational Company of The Year 2011. ( Joint Winners)1. Pfizer India Ltd, 2. Glaxo SmithKline Pharmaceuticals Ltd.21.India’s Most Admired Hospital Chain 2011. Fortis Healthcare Ltd. 22.Biotech Research Company of The Year 2011. Adroit Biomed Ltd.23.India’s Most technically & scientifically advanced Pharmaceutical Manufacturing unit of the year 2011. Aanjaneya Lifecare Ltd.
Speaking on the Award Declarations, Mr Satya Brahma, Chairman of Network 7 Media Group said “ Pharmaleaders salute these shining stars who bagged these coveted Awards by a rare display of achievements & performed under a changed healthcare scenario”.
With an aptly theme of Generation Next Indian Pharma Leaders, Billionaire Minds, Drivers for Growth at 4th Annual Pharmaceutical Leadership Summit & Awards 2011, veterans of the India’s Healthcare Industry debated on many topics that grappled Indian Healthcare segments. In an opening address, Mr Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders Magazine ( www.pharmaleaders.co.in ) said “ Indian Healthcare Industry has emerged out as a global super Power & has displayed remarkable display of manufacturing excellence & quality medicines & is way ahead of many developed nations, it is only a matter of time that it will overtake China in coming days, he added. He also lamented at Policy Makers & Authorities for slow decision making process specially in the context of Draft Pricing Policy & FDI in Healthcare Sector & urged the Ministry to hear the voices of the healthcare industry”.
Amonth those who addressed at Asia’s Biggest Leadership Meet are Mr. S. Krishnakumar (KK), Market Leader ( Life Sciences)Future Steps ( A Korn/Ferry Company, Dr Lalit S Kanodia, President Indo-American Chamber of Commerce, (IACC), Western Region, & CMD, Datamatics Ltd. Should drug prices be regulated?Mr. Kewal Kanda, MD, Pfizer India Ltd.` India – An Emerging Pharmaceutical Powerhouse , Dr Ajit V Dangi, Board Chairman, Fulford India Ltd. President & CEO, Danseen Consulting. Dr. Rashmi Barbhaiya , CEO and Managing Director - Advinus Therapeutics Ltd “From Scientist To CEO. The vision: Create a Pharmaceutical company focused on discovering and developing the next generation of high end commercialized medicines.Recent Advancements in Blood & Biological products :Mr Sanjay Bawsay, Managing Director, Synergy Diagnostics Pvt Ltd. Human biotechnology research in India, with emphasis on the BBIL story.Mr. Sai D Prasad, Project Manager - Rotavirus Vaccine Project and Vice President - Business Development. Are FDI & Price Control Policy in Indian Pharma Sector deterrent for growth & Globalize Indian Healthcare Industry. Mr. Shashikant B. Shinde ,Whole Time Director, AanjaneyaLifecare Ltd. Differentiate or Die - Pharmaceutical Industry in India. Mr.DeepakNaik, Managing Director Health 'N' U Therapeutics Pvt. Ltd. MrAnand Desai, National President, IACC & Managing Partner, DSK Legal : Do Pharmaceutical Companies Have Debt Crisis Strategy?. A Legal Perspective. Mr Narayan Gad, CEO, Formulations, Panacea Biotech Ltd. Moving Beyond the Healthcare Debate : The Transformative Trends That Will REALLY Define Our Future. Pharma’s Value Proposition - How The Industry Must Change. Perspectives On Current Industry Challenges .Mr. Sunil Madhok, Director, Business Development, Pfizer India Ltd.
More details of the post event are available on requests at editor.in.chief@pharmaleaders.co.in .
Sunday, December 4, 2011
Watch Pfizer Chief Kewal Handa As He Speaks On His Perspectives of The Controversial Draft Pharma Pricing Policy
Indian Healthcare Industry’s leading voice & one of the most respected name in the pharmaceutical sector, Mr Kewal Handa who strategies world’s leading drugmaker Pfizer in Indian operation will be speaking exclusively via televised tape on how The Centre’s decision to decontrol drug prices would take essential medicines beyond the reach of the common citizen. The controversial policy has been a bone of contention in the industry as there are no takers as the key pharma firms flay ‘populist' draft policy. The draft NPPP-2011 has been circulated among the concerned Ministries/Stake holders asking them for the feedbank.Patented drugs are not defined in the drugs (Price Control) Order, 1995 (DPCO, 1995). Under the provisions of the DPCO, 1995, prices of 74 scheduled bulk drugs and the formulations containing any of these scheduled drugs are controlled. National Pharmaceutical Pricing Authority (NPPA) fixes or revises prices of scheduled drugs / formulations as per the provisions of the DPCO, 1995. Anti-cancer medicines are non-scheduled drugs, i.e. not covered under DPCO, 1995. In respect of non-scheduled drugs, manufacturers are at liberty to fix the prices by themselves without seeking the approval of Government / NPPA. Department of Pharmaceuticals has prepared a draft National Pharmaceutical Pricing Policy 2011 (NPPP-2011) based on the criteria of essentiality and requirements as stipulated by the Ministry of Health & Family Welfare. The draft Policy envisages bringing the National List of Essential Medicines (NLEM) – 2011 and associated medicines under price control. The draft NPPP-2011 has been circulated among the concerned Ministries/Stake holders asking them for the feedbank. This information was given by the Minister of State for Chemicals and Fertilisers, Srikant Kumar Jena in a written reply in the Lok Sabha recently.
Handa speaks exclusively at the 4th Annual Pharmaceutical Leadership Summit 2011(www.pharmasummit.in ) organised by Pharmaleaders ( www.pharmaleaders.co.in ) to be held in Mumbai ob 10th December 2011 via Careworld TV. Mr Handa has strong reservations on the proposed policy as he feels that this will have detrimental effect on the healthcare sector. Kewal Handa is Managing Director, Pfizer Limited, the world’s No.1 pharmaceutical company that discovers and develops break-through drugs, provides information on prevention, wellness, and treatment; consistent high-quality manufacturing of medicines, consumer products; and is a global leader in corporate responsibility. Under his leadership, the company is now aggressive in its growth plans and has launched several new products.
Kewal is a reputed industry expert who takes the lead on key issues that concern the pharmaceutical sector. As Vice President of the Organisation of Pharmaceutical Producers of India (OPPI), he has been at the forefront of the industry’s efforts to resolve issues pertaining to the pharmaceutical sector. He is also the Chairman of DPCO & Taxation Committee of OPPI. He has recently been appointed as the President of All India Management Association and is a committee member of various industry bodies in the country. Kewal was awarded the ‘India CFO 2004 – Excellence in Finance in an MNC’ by International Market – Assessment Group and has recently won the Bharat Shiromani Award. A qualified Management Accountant and Company Secretary, and with a Masters Degree in Commerce from Sydenham College, Mumbai, Kewal has completed the Pfizer Leadership Development Program from Harvard University, the Senior Management Development Program from IIM, Ahmedabad. He has also done a course on Marketing Strategy from Columbia Business School. Mr. Handa is also the Managing Director of Wyeth Ltd.
Subscribe to:
Posts (Atom)